Category: Merck
-
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the…
-
STAT+: Merck is urged by patient groups to ensure widespread access to an HIV prevention pill being tested
STAT+: Merck is urged by patient groups to ensure widespread access to an HIV prevention pill being tested In a preemptive move, more than 170 patient advocacy groups from 30 countries are urging Merck to create a global access strategy for an HIV prevention pill, which is still being studied in clinical trials. A key,…
-
STAT+: With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition
STAT+: With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition SAN FRANCISCO — Investors attending the J.P. Morgan Healthcare Conference packed themselves into a hotel meeting room Monday to hear Revolution Medicines CEO Mark Goldsmith explain why Merck — or some other pharma buyer — should pay $30 billion…
-
Merck’s heart disease win and the FDA’s new drug regulator
Merck’s heart disease win and the FDA’s new drug regulator What does Rick Pazdur’s new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li, the head of R&D at Merck, joins us to discuss…
-
STAT+: Merck’s pill to reduce cholesterol on top of statins matches results from injectables
STAT+: Merck’s pill to reduce cholesterol on top of statins matches results from injectables NEW ORLEANS — A pill designed to further lower cholesterol in people already on statins but at risk of a serious cardiovascular event — their first or a recurrence — reduced LDL cholesterol by up to 60%, a new late-stage trial…
-
Pharma sours on the U.K., plus biotech M&A’s quiet roll
Pharma sours on the U.K., plus biotech M&A’s quiet roll Are pharmaceutical companies pulling their money out of the United Kingdom because of Trump? How is biotech M&A pacing this year? And what will vaccine advisors discuss at their closely watched meeting this week? We discuss all that and more on this week’s episode of…
-
Merck’s RSV antibody treatment for infants is approved by FDA
Merck’s RSV antibody treatment for infants is approved by FDA A third monoclonal antibody product to protect babies against respiratory syncytial virus was approved by the Food and Drug Administration on Monday, a development public health experts hope may eventually help to bring down the price of this effective but costly way of reducing the…